About: Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic
Creator	Gelfand, Joel Shin, Daniel Wan, Marilyn Winthrop, Kevin Shah, Mohsin Syed, Maha
Source	Elsevier; Medline; PMC
abstract	covid:6896cdcfb2dc257edda109c9448e6d5cc6c7b0b9#abstract
has issue date	2020-08-26(xsd:dateTime)
bibo:doi	10.1016/j.jaad.2020.08.095
bibo:pmid	32860913
has license	els-covid
sha1sum (hex)	6896cdcfb2dc257edda109c9448e6d5cc6c7b0b9
schema:url	https://doi.org/10.1016/j.jaad.2020.08.095
resource representing a document's title	Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic
has PubMed Central identifier	PMC7448776
has PubMed identifier	32860913
schema:publication	J Am Acad Dermatol
resource representing a document's body	covid:6896cdcfb2dc257edda109c9448e6d5cc6c7b0b9#body_text
is schema:about of	named entity 'pivotal' named entity 'psoriasis' named entity 'COVID-19 pandemic' named entity 'phase 3 trials' named entity 'decision-making' named entity 'tumor necrosis factor' named entity 'psoriasis' named entity 'respiratory tract' named entity 'phase 3 trials' named entity 'COVID-19 pandemic' named entity 'decision-making' named entity 'psoriasis' named entity 'PRE' named entity 'PHASE 3' named entity 'SYMPTOMS' named entity 'RESPIRATORY TRACT INFECTIONS' named entity 'ANTI-TUMOR NECROSIS FACTOR THERAPY' named entity 'RISK OF' named entity 'respiratory tract infections' named entity 'tumor necrosis factor' named entity 'necrosis' named entity 'patients' named entity 'decision-making' named entity 'respiratory tract infections' named entity 'phase' named entity 'EFFECT' named entity 'PSORIASIS' named entity 'PROOF' named entity 'JOURNAL ' named entity 'PATIENTS' named entity 'ESTIMATE' named entity 'META' named entity 'RELATED' named entity 'Journal' named entity 'risk' named entity 'pandemic' named entity 'COVID-19' named entity 'symptoms' named entity 'anti-tumor' named entity 'therapy' named entity 'DECISION-MAKING' named entity 'COVID-19 PANDEMIC' named entity 'RELEVANT'
is part of of	covid:6896cdcfb2dc257edda109c9448e6d5cc6c7b0b9#abstract covid:6896cdcfb2dc257edda109c9448e6d5cc6c7b0b9#body_text Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software